Global Drug-Device Combination Market Set To Grow To $184bn By 2021

13 August 2018
Pharma

Visiongain has launched a new pharma report Global Drug-Device Combination Market 2017-2027: Drug Eluting Stents, Photosensitizers, Orthopaedic Products, Infusion Pumps, Wound Care Products, Transmucosal Products, Transdermal Patches, Hospital & Clinics, Ambulatory Surgical Centres, Emergency Service Centres, Home Care Settings

Combination products are being increasingly used in patients suffering from chronic disorders such as cardiac disease, cancer, diabetes, and multiple sclerosis among others. Owing to these products, a new dynamic has been initiated in the medical product development, regulatory approval as well as corporate interaction. Over the last decade, various regulatory agencies have developed numerous competences and regulations due to the rising integration of drugs and devices occurring in the latest generation of combination products.

The lead analyst of the report commented “the Drug-Device combination market is driven by initiatives from governments and NGOs in support of drug delivery implants, a rise in the usage of minimally invasive surgeries, technological innovations and advancements, and increasing prevalence of chronic disorders. However, regulatory challenges pertaining to recall of products due to adverse effects, technical challenges related to drug delivery and higher cost of the products are some of the factors hampering the growth of the Drug-Device combination market.”

Leading companies featured in the report include Medtronic, Boston Scientific Corporation, Stryker Corporation, Ethicon Inc, C.R. Bard Inc., Medline Industries Inc., Mylan Inc., Terumo Corporation, Pinnacle Biologics Inc., and W. L. Gore & Associates, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031

Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.

13 November 2020

Read

Visiongain Publishes Antibacterial Drugs Market Report 2021-2031

The prevalence of bacterial diseases is significantly growing and expected to continuously rise over the forecast period. Number of bacterial diseases cases are increasing, like, bugs biting, including ticks, mosquitoes, lice and from an infected animal, contaminated food or water.

13 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever